Rimonabant is a drug from a French pharma outfit whose clinical trials show remarkable results in controlling appetite with minimal side-effects. It's being hailed as a drug with the potential to practically address the obesity epidemic.
Dr. Despres led a trial of rimonabant in 1,036 overweight patients at high risk for heart problems. All patients were told to cut their food intake by 600 calories daily. Those who received a 20-mg dose lost an average of 20 pounds and trimmed their waistlines by three inches in one year. Those given placebos lost an average of five pounds.Link